Tests letrozole added to maintenance treatment in estrogen receptor positive ovarian cancer
Tests letrozole or placebo alongside standard maintenance in adults with ovarian cancer.
Plain-language title generated from the registry record
Registry title: MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Key facts
- Where
- Graz, Innsbruck, Leoben, Linz, Salzburg, and Vienna, AustriaSee the 8 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Have you ever been told you have ovarian, fallopian tube or peritoneal cancer?
- What type of ovarian cancer do you have?
Source: NCT04111978, who can take part
Where in Austria
- Krankenhaus Der Barmherzigen BruederGraz, AustriaTaking people
- Medical University of GrazGraz, AustriaTaking people
- Medizinische Universitaet InnsbruckInnsbruck, AustriaTaking people
- Steiermaerkische Krankenanstalten Ges.m.b.H.Leoben, AustriaTaking people
- Krankenhaus Der Barmherzigen Schwestern Wien Betriebsgesellschaft mbHLinz, AustriaTaking people
- Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbHSalzburg, AustriaTaking people
- Klinik HietzingVienna, AustriaTaking people
- Medical University of ViennaVienna, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Swiss GO Trial Group
- Trial code
- NCT04111978EU 2024-511219-78-00
- Record updated
- 29 September 2025
- Original description
The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) and subsequent primary treatment surgery and chemotherapy. Half of the participants will receive to the standard maintenance treatment, letrozole, whilst the other half receives placebo.Read full original descriptionShow less
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study).
The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) and subsequent primary treatment surgery and chemotherapy. Half of the participants will receive to the standard maintenance treatment, letrozole, whilst the other half receives placebo.
The study's primary hypothesis is that the treatment with letrozole increases progression free survival in comparison to the maintenance standard treatment (superiority trial).
Inclusion: Patients must be ≥ 18 years of age; Willing and able to attend the visits and to understand all study-related procedures; Primary, newly diagnosed FIGO Stage II to IV and histologically confirmed low or high grade serous or endometrioid epithelial ovarian/fallopian tube/peritoneal cancer; (Interval-) debulking performed ECOG-Performance Status 0-2; Signed informed consents (ICF-1; ICF-2); Paraffin-embedded tissue or paraffin-embedded cell block (from ascites) available; Positivity (≥ 1%) for ER expression (only determined by Histopathology Core Facility of MATAO trial); At least 4 cycles of platinum-based chemotherapy (neoadjuvant allowed); Negative serum pregnancy test in women of childbearing potential who will get/have gotten a surgical resection or radiation sterilization, prior to the intervention in the therapeutical maintenance setting.
Exclusion: Women of childbearing potential (not having undergone a surgical or radiation sterilization and not getting a surgical resection, prior to the intervention in the therapeutical maintenance setting); < 4 cycles of chemotherapy in total; Contraindications to endocrine therapy; Progressive disease at the end of adjuvant treatment as defined in chapter 9.2.1 of protocol; Any other malignancy within the last 5 years which has impact on the prognosis of the patient; Patients with a known intolerance to galactose, lactase deficiency and glucose-galactose malabsorption; Pregnant or lactating women; Inability or unwillingness to swallow tablets.